Neuroplastic Agent Dosing for Faster Prosthetic Assimilation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are challenges in assimilating to new prosthetics, treating infertility, managing nonalcoholic fatty liver disease (NAFLD) and its advanced forms like nonalcoholic steatohepatitis (NASH), and addressing mental health issues such as insomnia and hormonal imbalances, which current treatments are inadequate or have significant side effects.
Innovation Solution
Administering a therapeutically-effective dose of neuroplastic agents like psilocybin, psilocin, or other tryptamines to promote neuroplasticity, which can treat conditions by improving assimilation to prosthetics, regulating minerals and hormones, reducing inflammation, and enhancing liver health, while minimizing side effects through controlled dosing regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for infertility are used, then conception rates remain low, but the risk of age-related infertility increases with advancing maternal age
Solution Approach 1:
The patent applies parameter changes by modifying hormonal parameters through neuroplastic agents that influence the endocrine system. The treatment changes the biochemical parameters of the reproductive system, including hormone levels and neural signaling, to improve conception rates and reduce time to conceive in age-related infertility cases
2Reliability
If GLP-1 receptor agonists are administered to treat NAFLD, then weight loss and liver inflammation reduction are achieved, but mental health side effects such as insomnia, anxiety, and depression occur
Solution Approach 1:
The patent extracts the harmful mental health side effects by using neuroplastic agents that specifically target liver pathology through neuroendocrine pathways while avoiding the psychiatric side effects associated with GLP-1 agonists. This separates the therapeutic liver benefits from the harmful mental health effects
Solution Approach 2:
The patent introduces neuroplastic agents as intermediary substances that mediate between the nervous system and liver metabolism. These agents act through neuroendocrine pathways to treat NAFLD without directly stimulating the receptors that cause mental health side effects in GLP-1 agonists
3Ease of operation
If prosthetic devices are designed to function intuitively, then user assimilation is improved, but a learning curve still exists for adaptation
Solution Approach 1:
The patent applies parameter changes by using neuroplastic agents to accelerate neural adaptation parameters. The treatment modifies neural plasticity parameters and synaptic connectivity rates, enabling faster brain-prosthetic interface adaptation and reducing the learning curve for prosthetic assimilation
Data Source
AI summary
Various aspects of this disclosure relate to methods to treat health conditions in human patients, comprising administering a therapeutically-effective dose of a neuroplastic agent. Various aspects of this disclosure relate to method to assimilate human patients to prosthetics, comprising administering a therapeutically-effective dose of a neuroplastic agent. In some embodiments, the neuroplastic agent is a tryptamine such as psilocybin or psilocin.